Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $4.08
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.32M
Market Cap
$423.77M
Enterprise Value$124.64M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 19, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding137,589,170
10 Day Avg. Volume1,217,048
30 Day Avg. Volume2,316,996
Standard Deviation0.32
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)547.12
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-65.95
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$10.00Price Target Upside242.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Compass Therapeutics News
See All CMPX News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe lead program, tovecimig, is set for a data readout from its pivotal Phase 2/3 trial, COMPANION-002, and prior data suggests the trial should report efficacy supporting regulatory approval.
Market PotentialTovecimig has demonstrated promising early clinical data in combination with Paclitaxel in biliary tract cancer where there are currently limited treatment options.
Bears Say
Data LimitationsThe absence of DOR and mPFS/OS data from the topline disclosure might serve to limit upside associated with a potential primary endpoint win.
---
Ownership Overview
4.99% Insiders
5.38% Mutual Funds
55.30% Other Institutional Investors
27.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $0.77 and its highest was $4.08 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $423.77M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 25 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.033.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 137,589,170 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went down -5.789%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
---
Compass Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (242.47% Upside)
$10.00 (242.47% Upside)
Hedge Fund Trend
Increased
By 3.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.48%
12-Months-Change
Fundamentals
Return on Equity
-32.01%
Trailing 12-Months
Asset Growth
-12.28%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
---
CMPX Stock 12 Month Forecast
Average Price Target
$10.00
▲(242.47% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Allogene Therapeutics
―
ADC Therapeutics
―
Best Analysts Covering CMPX
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+71.23%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +71.23% per trade.
---